Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:ALIM
- CUSIP: N/A
- Web: www.alimerasciences.com
Capitalization:- Market Cap: $96.67 million
- Outstanding Shares: 69,050,000
Average Prices:- 50 Day Moving Avg: $1.47
- 200 Day Moving Avg: $1.41
- 52 Week Range: $1.03 - $1.72
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -17.50
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $35.96 million
- Price / Sales: 2.69
- Book Value: ($0.70) per share
- Price / Book: -2.00
Profitability:- EBIDTA: ($16,780,000.00)
- Net Margins: -68.58%
- Return on Assets: -36.39%
Debt:- Debt-to-Equity Ratio: -0.72%
- Current Ratio: 4.63%
- Quick Ratio: 4.51%
Misc:- Average Volume: 305,717 shs.
- Beta: 2.16
- Short Ratio: 1.77
Frequently Asked Questions for Alimera Sciences (NASDAQ:ALIM)
What is Alimera Sciences' stock symbol?
Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."
How were Alimera Sciences' earnings last quarter?
Alimera Sciences, Inc. (NASDAQ:ALIM) released its earnings results on Wednesday, August, 2nd. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The firm earned $10.40 million during the quarter, compared to the consensus estimate of $10.20 million. The company's revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.17) EPS. View Alimera Sciences' Earnings History.
When will Alimera Sciences make its next earnings announcement?
Where is Alimera Sciences' stock going? Where will Alimera Sciences' stock price be in 2017?
3 brokers have issued 12 month price objectives for Alimera Sciences' shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate Alimera Sciences' stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Alimera Sciences.
What are analysts saying about Alimera Sciences stock?
Here are some recent quotes from research analysts about Alimera Sciences stock:
- 1. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (8/17/2017)
- 2. Cowen and Company analysts commented, "Positive Iluvien results were published in the journal Eye" for the treatment of DME." (7/25/2017)
Who are some of Alimera Sciences' key competitors?
Some companies that are related to Alimera Sciences include Kamada (KMDA), Peregrine Pharmaceuticals (PPHM), MediWound (MDWD), Kadmon Holdings (KDMN), Vericel Corporation (VCEL), VIVUS (VVUS), Cardiome Pharma Corporation (CRME), KalVista Pharmaceuticals (KALV), Chiasma (CHMA), Mirna Therapeutics (MIRN), Cesca Therapeutics (KOOL), Tokai Pharmaceuticals (NVUS), Sonoma Pharmaceuticals (SNOA), Ocera Therapeutics (OCRX), Onconova Therapeutics (ONTX), Catalyst Biosciences (CBIO), Argos Therapeutics (ARGS) and Auxilium Pharmaceuticals (AUXL).
Who are Alimera Sciences' key executives?
Alimera Sciences' management team includes the folowing people:
- Richard S. Eiswirth Jr., President, Chief Financial Officer
- Rich Cockrell, President
- C. Daniel Myers, Chief Executive Officer
- Kenneth E. Green Ph.D., Senior Vice President, Chief Scientific Officer
- David R. Holland, Senior Vice President - Sales and Marketing
- Philip Ashman, Senior Vice President, European Managing Director
- Mark J. Brooks, Independent Director
- Brian K. Halak Ph.D., Independent Director
- Peter J. Pizzo III, Independent Director
Who owns Alimera Sciences stock?
Alimera Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Palo Alto Investors LLC (4.60%), Vanguard Group Inc. (2.47%), JW Asset Management LLC (1.49%), Goldman Sachs Group Inc. (0.46%), Parkwood LLC (0.35%) and Stonepine Capital Management LLC (0.28%). Company insiders that own Alimera Sciences stock include C Daniel Myers, Calvin W Roberts, James E Flynn, LP Bavp, Richard S Eiswirth Jr and Richard S Eiswirth, Jr. View Institutional Ownership Trends for Alimera Sciences.
Who sold Alimera Sciences stock? Who is selling Alimera Sciences stock?
Alimera Sciences' stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Vanguard Group Inc. and Goldman Sachs Group Inc.. Company insiders that have sold Alimera Sciences stock in the last year include C Daniel Myers and Richard S Eiswirth Jr. View Insider Buying and Selling for Alimera Sciences.
Who bought Alimera Sciences stock? Who is buying Alimera Sciences stock?
Alimera Sciences' stock was bought by a variety of institutional investors in the last quarter, including JW Asset Management LLC and PNC Financial Services Group Inc.. Company insiders that have bought Alimera Sciences stock in the last two years include Calvin W Roberts and James E Flynn. View Insider Buying and Selling for Alimera Sciences.
How do I buy Alimera Sciences stock?
Shares of Alimera Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alimera Sciences' stock price today?
One share of Alimera Sciences stock can currently be purchased for approximately $1.40.
MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Alimera Sciences (NASDAQ:ALIM)Earnings History by Quarter for Alimera Sciences (NASDAQ ALIM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($0.05) | | | | | N/A |  |
| 8/2/2017 | Q2 2017 | ($0.05) | ($0.04) | $10.20 million | $10.40 million | View | Listen | |
| 5/8/2017 | Q1 2017 | ($0.08) | ($0.10) | $8.80 million | $6.62 million | View | Listen | |
| 3/1/2017 | Q4 2016 | ($0.07) | ($0.10) | $10.60 million | $10.70 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.11) | ($0.16) | $10.53 million | $8.30 million | View | N/A | |
| 8/3/2016 | Q2 | ($0.19) | ($0.17) | $8.42 million | $3.80 million | View | N/A | |
| 5/4/2016 | Q1 | ($0.19) | ($0.22) | $5.83 million | $5.80 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.22) | ($0.21) | $6.96 million | $6.90 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.22) | ($0.25) | $6.49 million | $5.80 million | View | Listen | |
| 5/7/2015 | Q115 | ($0.24) | ($0.27) | $3.90 million | $3.90 million | View | N/A | |
| 3/4/2015 | Q414 | ($0.16) | ($0.28) | $5.11 million | $1.70 million | View | N/A | |
| 11/6/2014 | Q314 | ($0.70) | ($0.22) | $3.75 million | $2.40 million | View | N/A | |
| 8/7/2014 | Q214 | ($0.23) | ($0.15) | $2.70 million | $2.19 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.25) | ($0.20) | $1.15 million | $2.08 million | View | N/A | |
| 2/27/2014 | Q413 | ($0.29) | ($0.24) | $0.75 million | $0.94 million | View | N/A | |
| 11/11/2013 | Q313 | ($0.30) | ($0.26) | $0.38 million | $0.76 million | View | N/A | |
| 8/12/2013 | Q2 2013 | ($0.24) | ($0.30) | $3.00 million | | View | N/A | |
| 5/9/2013 | Q1 2013 | ($0.26) | ($0.27) | | | View | N/A | |
| 3/21/2013 | Q4 2012 | ($0.23) | ($0.17) | | | View | N/A | |
| 11/7/2012 | Q312 | ($0.19) | ($0.17) | | | View | N/A | |
| 3/8/2012 | | ($0.24) | ($0.19) | | | View | N/A | |
| 11/3/2011 | | ($0.19) | ($0.21) | | | View | N/A | |
| 8/4/2011 | | ($0.18) | ($0.17) | | | View | N/A | |
| 5/5/2011 | | ($0.20) | ($0.15) | | | View | N/A | |
| 2/10/2011 | | ($0.22) | ($0.20) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Alimera Sciences (NASDAQ:ALIM)Current Year EPS Consensus Estimate: $-0.21 EPS
Next Year EPS Consensus Estimate: $-0.08 EPS
Dividend History for Alimera Sciences (NASDAQ:ALIM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Alimera Sciences (NASDAQ:ALIM)Insider Ownership Percentage: 14.00%
Institutional Ownership Percentage: 43.77%
Insider Trades by Quarter for Alimera Sciences (NASDAQ:ALIM)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/10/2017 | C. Daniel Myers | CEO | Sell | 21,172 | $1.39 | $29,429.08 | |
| 9/15/2016 | Richard S Eiswirth Jr | Insider | Sell | 51,471 | $1.51 | $77,721.21 | |
| 4/21/2016 | L.P. Bavp | Major Shareholder | Sell | 478,673 | $2.59 | $1,239,763.07 | |
| 12/16/2015 | Richard S. Eiswirth, Jr. | CFO | Sell | 46,669 | $2.31 | $107,805.39 | |
| 12/8/2015 | James E Flynn | Insider | Buy | 272,249 | $3.01 | $819,469.49 | |
| 12/3/2015 | James E Flynn | Insider | Buy | 243,252 | $3.00 | $729,756.00 | |
| 10/30/2015 | James E Flynn | Insider | Buy | 16,542 | $3.00 | $49,626.00 | |
| 10/28/2015 | James E Flynn | Insider | Buy | 59,342 | $3.00 | $178,026.00 | |
| 10/26/2015 | James E Flynn | Insider | Buy | 60,364 | $3.00 | $181,092.00 | |
| 10/21/2015 | James E Flynn | Major Shareholder | Buy | 160,684 | $3.00 | $482,052.00 | |
| 10/20/2015 | James E Flynn | Major Shareholder | Buy | 100,130 | $3.00 | $300,390.00 | |
| 10/19/2015 | James E Flynn | Major Shareholder | Buy | 129,226 | $2.92 | $377,339.92 | |
| 10/15/2015 | Richard S. Eiswirth, Jr. | CFO | Sell | 13,625 | $2.69 | $36,651.25 | |
| 10/9/2015 | James E Flynn | Insider | Buy | 321,785 | $2.42 | $778,719.70 | |
| 9/3/2015 | Calvin W Roberts | Director | Buy | 6,424 | $3.00 | $19,272.00 | |
| 8/21/2015 | Kenneth Green | SVP | Sell | 20,000 | $3.29 | $65,800.00 | |
| 8/17/2015 | Kenneth Green | SVP | Sell | 20,000 | $3.90 | $78,000.00 | |
| 6/26/2015 | L.P. Bavp | Major Shareholder | Sell | 1,024 | $5.00 | $5,120.00 | |
| 6/19/2015 | L.P. Bavp | Major Shareholder | Sell | 5,568 | $5.00 | $27,840.00 | |
| 5/1/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $4.37 | $8,740.00 | |
| 4/27/2015 | L.P. Bavp | Major Shareholder | Sell | 3,114 | $5.02 | $15,632.28 | |
| 4/23/2015 | L.P. Bavp | Major Shareholder | Sell | 4,362 | $5.00 | $21,810.00 | |
| 4/20/2015 | L.P. Bavp | Major Shareholder | Sell | 30,300 | $5.03 | $152,409.00 | |
| 4/15/2015 | L.P. Bavp | Major Shareholder | Sell | 35,800 | $5.03 | $180,074.00 | |
| 4/14/2015 | L.P. Bavp | Major Shareholder | Sell | 18,400 | $5.01 | $92,184.00 | |
| 4/13/2015 | L.P. Bavp | Major Shareholder | Sell | 100 | $5.00 | $500.00 | |
| 3/6/2015 | Richard S Eiswirth Jr | CFO | Buy | 10,000 | $4.84 | $48,400.00 | |
| 3/2/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $5.21 | $10,420.00 | |
| 1/2/2015 | C. Daniel Myers | CEO | Sell | 2,000 | $5.51 | $11,020.00 | |
| 1/2/2015 | David Holland | SVP | Sell | 5,000 | $5.56 | $27,800.00 | |
| 12/1/2014 | C. Daniel Myers | CEO | Sell | 2,000 | $5.99 | $11,980.00 | |
| 12/1/2014 | David Holland | SVP | Sell | 5,000 | $5.71 | $28,550.00 | |
| 10/27/2014 | L.P. Bavp | Major Shareholder | Sell | 57,918 | $6.34 | $367,200.12 | |
| 10/1/2014 | C. Daniel Myers | CEO | Sell | 2,000 | $5.42 | $10,840.00 | |
| 10/1/2014 | David Holland | SVP | Sell | 5,000 | $5.26 | $26,300.00 | |
| 10/1/2014 | Patrick Lee | Major Shareholder | Sell | 621,191 | $5.42 | $3,366,855.22 | |
| 9/30/2014 | Patrick Lee | Major Shareholder | Sell | 354,062 | $5.42 | $1,919,016.04 | |
| 9/29/2014 | Patrick Lee | Major Shareholder | Sell | 240,662 | $5.47 | $1,316,421.14 | |
| 9/11/2014 | L.P. Bavp | Major Shareholder | Sell | 2,816 | $6.25 | $17,600.00 | |
| 9/4/2014 | L.P. Bavp | Major Shareholder | Sell | 39,500 | $6.33 | $250,035.00 | |
| 8/29/2014 | L.P. Bavp | Major Shareholder | Sell | 7,400 | $6.27 | $46,398.00 | |
| 8/28/2014 | L.P. Bavp | Major Shareholder | Sell | 3,000 | $6.27 | $18,810.00 | |
| 8/1/2014 | David Holland | SVP | Sell | 5,000 | $5.64 | $28,200.00 | |
| 7/1/2014 | David Holland | SVP | Sell | 5,000 | $6.02 | $30,100.00 | |
| 5/1/2014 | David Holland | SVP | Sell | 5,000 | $5.93 | $29,650.00 | |
| 3/4/2014 | C. Daniel Myers | CEO | Sell | 22,775 | $7.10 | $161,702.50 | |
| 3/4/2014 | David Holland | SVP | Sell | 10,000 | $6.84 | $68,400.00 | |
| 3/4/2014 | Susan Caballa | Insider | Sell | 8,931 | $7.01 | $62,606.31 | |
| 1/16/2014 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 296,760 | $6.39 | $1,896,296.40 | |
| 7/17/2013 | Polaris Venture Management Co | Insider | Sell | 122,937 | $4.80 | $590,097.60 | |
| 6/20/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 10,516 | $5.01 | $52,685.16 | |
| 6/19/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 55,278 | $5.39 | $297,948.42 | |
| 6/18/2013 | Polaris Venture Management Co | Insider | Sell | 37,063 | $5.44 | $201,622.72 | |
| 6/17/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 126,709 | $5.29 | $670,290.61 | |
| 6/11/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 5,337 | $5.00 | $26,685.00 | |
| 5/17/2013 | David Holland | SVP | Sell | 30,000 | $4.13 | $123,900.00 | |
| 5/16/2013 | Domain Partners Vi, L.P. | Major Shareholder | Sell | 44,242 | $4.60 | $203,513.20 | |
| 12/13/2012 | Peter J Pizzo III | Director | Buy | 5,000 | $1.44 | $7,200.00 | |
| 12/3/2012 | C. Daniel Myers | CEO | Sell | 7,700 | $1.95 | $15,015.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Alimera Sciences (NASDAQ:ALIM)
Latest Headlines for Alimera Sciences (NASDAQ:ALIM)
| Source: |
|
| Date | Headline |
|---|
 | Alimera Sciences, Inc. (ALIM) Downgraded by Zacks Investment Research
www.americanbankingnews.com - August 17 at 4:54 PM |
 | Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting - Nasdaq
www.nasdaq.com - August 9 at 8:58 PM |
 | Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting
finance.yahoo.com - August 9 at 3:56 PM |
| Alimera Sciences' CEO Dan Myers to Present US Real-World ILUVIEN® Post-Marketing Data During Ophthalmology ... - Nasdaq
www.nasdaq.com - August 9 at 1:23 AM |
 | Alimera Sciences' CEO Dan Myers to Present US Real-World ILUVIEN® Post-Marketing Data During Ophthalmology ... - GlobeNewswire (press release)
globenewswire.com - August 8 at 2:43 AM |
| Alimera Sciences' CEO Dan Myers to Present U.S. Real-World ILUVIEN® Post-Marketing Data During Ophthalmology Innovation Summit at ASRS, August 10, 2017
finance.yahoo.com - August 7 at 4:40 PM |
| HC Wainwright Reiterates "$5.00" Price Target for Alimera Sciences, Inc. (NASDAQ:ALIM)
www.americanbankingnews.com - August 6 at 10:26 PM |
 | Alimera Sciences' (ALIM) CEO Dan Myers on Q2 2017 Results ... - Seeking Alpha
seekingalpha.com - August 6 at 8:31 PM |
| Alimera Sciences, Inc. (NASDAQ:ALIM) Given a $3.00 Price Target by Cowen and Company Analysts
www.americanbankingnews.com - August 6 at 6:28 PM |
| Edited Transcript of ALIM earnings conference call or presentation 3-Aug-17 1:00pm GMT
finance.yahoo.com - August 5 at 3:32 PM |
| Alimera Sciences reports 2Q loss
finance.yahoo.com - August 3 at 4:43 PM |
| Alimera Sciences, Inc. (NASDAQ:ALIM) Releases Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - August 3 at 3:39 PM |
| Alimera Sciences Reports Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 3 at 1:41 AM |
| Alimera Sciences Reports Second Quarter 2017 Financial Results
www.nasdaq.com - August 2 at 8:40 PM |
| Comparing Alimera Sciences (NASDAQ:ALIM) & Sinovac Biotech (SVA)
www.americanbankingnews.com - July 28 at 7:49 AM |
 | BRIEF-Alimera Sciences announces real-world audit data supporting positive benefits of iluvien treatment
www.reuters.com - July 26 at 1:34 AM |
| Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN® Treatment - GlobeNewswire (press release)
globenewswire.com - July 25 at 8:34 PM |
| Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN® Treatment
finance.yahoo.com - July 25 at 8:34 PM |
| Alimera Sciences, Inc. (ALIM) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:06 AM |
| Alimera Sciences to Report Second Quarter 2017 Financial Results on August 2nd, 2017
finance.yahoo.com - July 24 at 1:26 PM |
 | Alimera Sciences (ALIM) Says MHRA Has Given Final Approval to Reduce Size of its ILUVIEN Registry Safety Study - StreetInsider.com
www.streetinsider.com - July 20 at 5:05 PM |
| Positive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN® Registry Safety Study in the UK - Nasdaq
www.nasdaq.com - July 19 at 4:54 PM |
| Positive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN® Registry Safety Study in the U.K.
finance.yahoo.com - July 19 at 4:54 PM |
| Leading Retinal Specialists to Highlight pSivida's Durasert for Treatment of Posterior Segment Uveitis at ... - Nasdaq
www.nasdaq.com - July 18 at 5:10 PM |
| Zacks Investment Research Lowers Alimera Sciences, Inc. (NASDAQ:ALIM) to Hold
www.americanbankingnews.com - July 13 at 7:14 PM |
| ETFs with exposure to Alimera Sciences, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 4:30 PM |
| Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN® - Nasdaq
www.nasdaq.com - July 12 at 4:09 PM |
| Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®
finance.yahoo.com - July 12 at 4:09 PM |
 | BRIEF-Psivida out-licenses EMEA rights for Durasert three-year treatment for posterior segment Uveitis
www.businessinsider.com - July 11 at 5:00 PM |
| Cowen and Company Reaffirms "Buy" Rating for Alimera Sciences, Inc. (NASDAQ:ALIM)
www.americanbankingnews.com - July 11 at 4:10 PM |
| pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining ... - GlobeNewswire (press release)
globenewswire.com - July 11 at 1:41 AM |
| Alimera Sciences To Expand ILUVIEN® Indication in Europe for Posterior Uveitis - GlobeNewswire (press release)
globenewswire.com - July 10 at 8:41 PM |
| pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSivida’s Revenue Generation
finance.yahoo.com - July 10 at 8:41 PM |
| Alimera Sciences To Expand ILUVIEN® Indication in Europe for Posterior Uveitis
finance.yahoo.com - July 10 at 8:41 PM |
| Alimera Sciences, Inc. (ALIM) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - July 10 at 4:09 PM |
| ETFs with exposure to Alimera Sciences, Inc. : June 29, 2017
finance.yahoo.com - June 29 at 4:42 PM |
| ETFs with exposure to Alimera Sciences, Inc. : June 29, 2017
finance.yahoo.com - June 29 at 4:42 PM |
| ETFs with exposure to Alimera Sciences, Inc. : June 16, 2017
finance.yahoo.com - June 16 at 4:04 PM |
| Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 3:28 PM |
 | Research Reports Initiation on Drug Makers Stocks -- Immune Pharma, Impax Labs, Heron Therapeutics, and Alimera Sciences
www.bizjournals.com - June 2 at 4:33 PM |
| Blog Coverage Eli Lilly's Late-Stage Bladder Cancer Drug CYRAMZA Meets Primary Endpoint
finance.yahoo.com - June 2 at 4:33 PM |
| Alimera Sciences' (ALIM) CEO Dan Myers on Q1 2017 Results ... - Seeking Alpha
seekingalpha.com - May 10 at 9:26 AM |
| Alimera Sciences Reports First Quarter 2017 Financial Results ... - GlobeNewswire (press release)
globenewswire.com - May 10 at 9:26 AM |
| Edited Transcript of ALIM earnings conference call or presentation 9-May-17 12:00pm GMT
finance.yahoo.com - May 9 at 8:28 PM |
| Alimera Sciences Inc (ALIM) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - May 9 at 10:22 AM |
| Investor Network: ALIMERA SCIENCES INC to Host Earnings Call
finance.yahoo.com - May 9 at 9:21 AM |
| Alimera Sciences Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 8:26 PM |
 | Alimera Sciences reports 1Q loss
marketbeat.com - May 8 at 6:22 PM |
| Alimera Sciences (ALIM) Receives Daily Media Impact Score of 0.24
www.americanbankingnews.com - May 4 at 3:54 PM |
| Alimera Sciences to Report First Quarter 2017 Financial Results on May 8th, 2017
finance.yahoo.com - May 3 at 3:28 PM |
Alimera Sciences (ALIM) Chart for Tuesday, August, 22, 2017
